🇧🇷Brazil

Erros de Decisão por Falta de Visibilidade em Tempo Real sobre Estoque de Medicamentos Controlados

3 verified sources

Definition

Controlled substances are high-value, regulated, and have strict shelf-life requirements. Poor inventory visibility leads to: (1) over-purchasing due to perceived low stock → expiration waste; (2) under-purchasing due to delayed reporting → stock-outs, lost sales, customer churn to competitors; (3) inability to optimize by-prescriber demand (e.g., surge in antidepressants in winter).

Key Findings

  • Financial Impact: LOGIC-based estimate: 2–5% inventory waste (expiration/spoilage) on R$ 100,000/month controlled-substance revenue = R$ 2,000–R$ 5,000/month. 5–10% stock-out-driven lost sales = R$ 5,000–R$ 10,000/month forgone margin. Combined: R$ 7,000–R$ 15,000/month per pharmacy. Network (50 locations): R$ 350,000–R$ 750,000/month. Annual: R$ 4.2M–R$ 9M.
  • Frequency: Continuous; manifests in monthly variance reports and lost-sale logs.
  • Root Cause: SNGPC reporting delay (batch vs. real-time); no predictive analytics on demand trends; purchasing decisions made by regional buyers with stale data; lack of integration between SNGPC and purchasing/procurement systems.

Why This Matters

The Pitch: Brazilian pharmacies waste 2–5% of controlled-substance purchases on expiration/waste and lose 5–10% of sales due to avoidable stock-outs. Real-time SNGPC-inventory integration provides up-to-the-minute visibility, reducing waste by 30–50% and stock-outs by 40–60%, generating R$ 20,000–R$ 80,000/year per pharmacy in recovered margin.

Affected Stakeholders

Pharmacy Manager (stock decisions), Regional Buyer / Procurement, Supply Chain Planner, Finance (variance analysis)

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Penalidades por Não-Conformidade ao SNGPC (Portaria 344/1998)

LOGIC-based estimate: Typical ANVISA administrative fines for non-compliance range R$ 5,000–R$ 50,000 per violation; larger networks face R$ 100,000+ for systemic SNGPC failures. Operational costs from license suspensions or revocation: loss of controlled-substance revenue (15–30% of pharmacy revenue), estimated R$ 50,000–R$ 500,000+ per pharmacy per month during suspension.

Atraso Operacional por Registro Manual no SNGPC (Sistema Nacional de Gerenciamento de Produtos Controlados)

LOGIC-based estimate: 2–5 minutes per controlled-substance transaction × 20–50 controlled transactions/day per pharmacy × 22 working days/month = 14.6–110 hours/month of technician time (R$ 880–R$ 6,600/month at R$ 60/hour blended cost). For pharmacy networks with 50+ locations: R$ 44,000–R$ 330,000/month in lost labor capacity.

Risco de Desvio e Furto de Medicamentos Controlados por Falta de Rastreabilidade em Tempo Real

LOGIC-based estimate: Average shrinkage rate 1–3% of controlled-substance inventory. For a mid-sized pharmacy (R$ 100,000/month in controlled-substance revenue): R$ 1,000–R$ 3,000/month loss. For pharmacy network (50 locations): R$ 50,000–R$ 150,000/month undetected shrinkage. Annual impact: R$ 600,000–R$ 1.8M per network.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Perda por Vencimento de Medicamentos (Product Expiration Waste)

Estimated: R$ 2,000–25,000 annually per pharmacy (2–5% of typical inventory value of R$ 100,000–500,000). Pharmacy chains with 10+ locations: R$ 20,000–250,000+ annually.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence